Sanofi's oral BTK inhibitor tolebrutinib is heading towards an FDA decision in September as a potential treatment for multiple sclerosis (MS) after a priority review by the US regulator. Tolebrutinib ...

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS). The ...

As supply chains continue to evolve, professionals in the industry are faced with the challenges and complexities of creating sustainable supply chains in their organizations. The need to gain ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

Use these 7 Microsoft promo codes to save on computer software, PCs, laptops and more. All coupon content is created by PC Gamer. We may earn a commission if you buy through our links. More Info.